International Journal of Molecular Sciences· 2026Q1· Review
Personalized Geriatric Pharmacotherapy: Pharmacogenomics, Polypharmacy, and Age-Related Pharmacokinetic and Pharmacodynamic Changes
- 0citations
- Q1SCImago
- 2026year
Short summary
A Q1-journal review outlines a framework for personalized geriatric pharmacotherapy, integrating pharmacogenomics and deprescribing to manage age-related changes in drug response and polypharmacy.
AI-generated from the title and abstract; the full text is not read.
Key points
- Aging causes physiological changes affecting drug disposition and response, narrowing therapeutic windows.
- Polypharmacy in older adults exacerbates risks through drug-drug and drug-gene interactions.
- Pharmacogenomic testing for specific CYP enzymes and SLCO1B1 can personalize geriatric therapy.
- Deprescribing frameworks offer practical methods to reduce medication-related risks.
AI-generated from the title and abstract; the full text is not read.
Abstract
Aging induces profound physiological changes that alter drug disposition and response, narrowing therapeutic windows and increasing susceptibility to adverse drug reactions (ADRs). This review synthesizes current evidence on age-related pharmacokinetic and pharmacodynamic changes, with a focus on pharmacogenomic determinants of drug response in older adults. Progressive decline in renal function, hepatic metabolic capacity, and alterations in body composition collectively necessitate age-appropriate dose adjustments. Polypharmacy, prevalent in community-dwelling and hospitalized older adults, compounds these challenges through drug–drug and drug–drug–gene interactions. Pharmacogenomic testing—particularly for CYP2D6, CYP2C19, CYP2C9, and SLCO1B1—offers a promising strategy to personalize therapy, while deprescribing frameworks provide practical approaches to mitigate medication-related risks. This review presents a comprehensive framework for understanding the mechanistic basis of altered drug response in older adults and proposes actionable strategies for optimizing pharmacotherapy in this vulnerable population.
The authors' abstract, as published at the source. International Journal of Molecular Sciences, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Pharmacology (Pharmacology, Toxicology and Pharmaceutics)
PharmacologyPharmacology, Toxicology and Pharmaceutics